FelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Follicular Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Follicular Lymphoma Market Forecast

Some of the key facts of the Follicular Lymphoma Market Report:

• The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY® (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies.

• In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025.

• In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025.

• In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies.

• In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM.

• In 2024, the United States generated around USD 1,082 million in revenue.

• In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million.

• In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million.

• Follicular lymphoma is an indolent variety of non-Hodgkin’s lymphoma (NHL) originating from germinal center B cells. Follicular lymphoma is one of the most prevalent forms of indolent B cell NHL. It has a long disease course due to the chronic incurable nature of the disease in the majority of patients.

• In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034.

• In 2024, the 60–80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40–59 age group with approximately 4,000 cases.

• In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases.

• In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases.

• Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others

• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others

• The Follicular Lymphoma epidemiology based on risk analyzed that low risk, intermediate risk and high risk patients contribute to 20%, 53% and 27% of all FL cases, respectively

• The Follicular Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics.

Follicular Lymphoma Overview

Follicular Lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), which is a cancer of the lymphatic system. It originates from B lymphocytes (B cells), a type of white blood cell that plays a crucial role in the immune system. Follicular Lymphoma is characterized by the formation of abnormal, usually slow-growing, lymphoid follicles in the lymph nodes.

Get a Free sample for the Follicular Lymphoma Market Report:

https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights

Follicular Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Follicular Lymphoma Epidemiology Segmentation:

The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Follicular Lymphoma

• Prevalent Cases of Follicular Lymphoma by severity

• Gender-specific Prevalence of Follicular Lymphoma

• Diagnosed Cases of Episodic and Chronic Follicular Lymphoma

Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ Follicular Lymphoma Epidemiology Forecast

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Follicular Lymphoma Therapies and Key Companies

• LUNSUMIO (mosunetuzumab): Roche

• BRUKINSA (zanubrutinib): BeiGene

• YESCARTA: Kite Pharma

• MONJUVI (tafasitamab): Incyte Corporation

• AZD0486: AstraZeneca

• Abexinostat: Xynomic Pharmaceuticals

• ME-401: MEI Pharma

• Tisagenlecleucel: Novartis

• Parsaclisib (IBI376): Innovent Biologics

• Odronextamab: Regeneron

• Mosunetuzumab: Genetech

• Abexinostat: Xynomic Pharma

• Rituximab IV: Roche

• Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche

• Enzastaurin: Eli Lilly and Company

• Loncastuximab tesirine: ADC Therapeutics S.A

• Zanubrutinib: BeiGene

• Bendamustine: Cephalon

• Tazemetostat: Epizyme, Inc.

• ibrutinib: Pharmacyclics LLC.

• Obatoclax mesylate: Gemin X

• Ibrutinib: AbbVie

• IXAZOMIB: Millennium Pharma

To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Clinical Trials and Therapeutic Assessment

Follicular Lymphoma Market Strengths

• Follicular lymphoma market has a diverse pipeline,with emergence of novel classes such as bi-specificantibodies, cancer vaccine and allogenic CAR-Ts.

Follicular Lymphoma Market Opportunities

• R-CHOP continues to be the gold standard of caredespite other therapies or combinations that have tried to advance the treatment paradigm

Scope of the Follicular Lymphoma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others

• Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others

• Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies

• Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Follicular Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Follicular Lymphoma Market Access and Reimbursement

Discover more about therapies set to grab major Follicular Lymphoma market share @ Follicular Lymphoma Treatment Landscape

Table of Contents

1. Follicular Lymphoma Market Report Introduction

2. Executive Summary for Follicular Lymphoma

3. SWOT analysis of Follicular Lymphoma

4. Follicular Lymphoma Patient Share (%) Overview at a Glance

5. Follicular Lymphoma Market Overview at a Glance

6. Follicular Lymphoma Disease Background and Overview

7. Follicular Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Follicular Lymphoma

9. Follicular Lymphoma Current Treatment and Medical Practices

10. Follicular Lymphoma Unmet Needs

11. Follicular Lymphoma Emerging Therapies

12. Follicular Lymphoma Market Outlook

13. Country-Wise Follicular Lymphoma Market Analysis (2020–2034)

14. Follicular Lymphoma Market Access and Reimbursement of Therapies

15. Follicular Lymphoma Market Drivers

16. Follicular Lymphoma Market Barriers

17. Follicular Lymphoma Appendix

18. Follicular Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/